Prostate-specific antigen response after short-term hormone therapy plus external-beam radiotherapy and outcome in patients treated on Radiation Therapy Oncology Group study 9413-Reference-Cited by-同舟云学术

Prostate-specific antigen response after short-term hormone therapy plus external-beam radiotherapy and outcome in patients treated on Radiation Therapy Oncology Group study 9413

Published:2013-03-15 Issue:11 Volume:119 Page:1999-2004
ISSN:0008-543X
Container-title:Cancer
language:en
Short-container-title:Cancer

Author:

Cury Fabio L.¹,Hunt Daniel²,Roach Mack³,Shipley William⁴,Gore Elizabeth⁵,Hsu I-Chow³,Krisch Robert E.⁶,Seider Michael J.⁷,Sandler Howard⁸,Lawton Colleen⁵

Affiliation:

1. Radiation Oncology; McGill University Health Centre; Montreal Quebec Canada

2. Radiation Therapy Oncology Group Statistical Center; Philadelphia Pennsylvania

3. Department of Radiation Oncology; University of California-San Francisco Helen Diller Comprehensive Cancer Center; San Francisco California

4. Department of Radiation Oncology; Massachusetts General Hospital; Boston Massachusetts

5. Radiation Oncology; Medical College of Wisconsin; Madison Wisconsin

6. Radiation Oncology; Hospital of the University of Pennsylvania; Philadelphia Pennsylvania

7. Radiation Oncology; Akron City Hospital; Akron Ohio

8. Radiation Oncology; Samuel Oschin Comprehensive Cancer Institute; Cedars-Sinai Medical Center; Los Angeles California

Publisher

Wiley

Subject

Cancer Research,Oncology

Link

http://onlinelibrary.wiley.com/wol1/doi/10.1002/cncr.28019/fullpdf

Reference23 articles.

1. Combining radiation therapy and androgen deprivation for localized prostate cancer-a critical review;Dal Pra;Curr Oncol.,2010

2. Side effects of androgen deprivation therapy: monitoring and minimizing toxicity;Higano;Urology.,2003

3. Pretreatment prostate-specific antigen (PSA) velocity and doubling time are associated with outcome but neither improves prediction of outcome beyond pretreatment PSA alone in patients treated with radical prostatectomy;O'Brien;J Clin Oncol.,2009

4. Pretreatment PSA velocity as a predictor of disease outcome following radical radiation therapy;Palma;Int J Radiat Oncol Biol Phys.,2007

5. Phase III trial comparing whole-pelvic versus prostate-only radiotherapy and neoadjuvant versus adjuvant combined androgen suppression: Radiation Therapy Oncology Group 9413;Roach;J Clin Oncol.,2003

Cited by 18 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Addition of Enzalutamide to Leuprolide and Definitive Radiation Therapy Is Tolerable and Effective in High-Risk Localized or Regional Nonmetastatic Prostate Cancer: Results From a Phase 2 Trial;Advances in Radiation Oncology;2022-09

2. Prostate-specific antigen kinetics and metastasis-free survival in patients treated with external beam radiotherapy combined with high-dose-rate brachytherapy boost and androgen deprivation therapy for localized prostate cancer;Journal of Contemporary Brachytherapy;2022

3. Combination of Radiation Therapy and Short-Term Androgen Blockade With Abiraterone Acetate Plus Prednisone for Men With High- and Intermediate-Risk Localized Prostate Cancer;International Journal of Radiation Oncology*Biology*Physics;2021-04

4. 18F-DCFPyL PET/CT for primary staging in 160 high-risk prostate cancer patients; metastasis detection rate, influence on clinical management and preliminary results of treatment efficacy;European Journal of Nuclear Medicine and Molecular Imaging;2020-07-27

5. Therapie bei isoliertem PSA-Anstieg;Uroonkologie;2020